Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Phytobiotech Raises C$17M For Plant-Derived Molecules

Sep. 26, 2002

By Aaron Lorenzo

StemCells Cutting Back To Focus On Neural, Liver Disease

Sep. 24, 2002

By Aaron Lorenzo

StemCells Cutting Back To Focus On Neural, Liver Disease

Sep. 24, 2002

By Aaron Lorenzo

eXegenics, IDDS Merging Via Stock Deal Valued At $46M

Sep. 23, 2002

By Aaron Lorenzo

eXegenics, IDDS Merging Via Stock Deal Valued At $46M

Sep. 23, 2002

By Aaron Lorenzo

Endovasc Creates Subsidiaries For Two Late-Stage Products

Sep. 20, 2002

By Aaron Lorenzo

Endovasc Creates Subsidiaries For Two Late-Stage Products

Sep. 20, 2002

By Aaron Lorenzo

Cellegy Resurrects Cellegesic, Set To Begin Third Phase III

Sep. 10, 2002

By Aaron Lorenzo

Cellegy Resurrects Cellegesic, Set To Begin Third Phase III

Sep. 10, 2002

By Aaron Lorenzo

LION Cutting Back On Drugs To Focus On Support Systems

Sep. 9, 2002

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 7, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
AI drives financings, approvals for APAC med-tech in 2024
BioWorld MedTech
AI pulled in major financings and approvals for Asia med-techs in 2024 as Asia Pacific countries played to individual strengths to maximize AI’s applications in...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.